SEC Tracker
Get the app

Helus Pharma HELP

Helus Pharma co-founders step down from executive roles

Foreign issuer report

Form
6-K
Filed
Importance
Notable
  1. Eric So and Paul Glavine stepped down from executive and consulting roles on October 26, 2026.
  2. Mark Lawson was appointed as independent Chair of the Board of Directors.
  3. Eric So was named Chairman Emeritus, an honorary title.
  4. The Board of Directors appointed Michael Halstead as CEO.

Written from the 6-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Helus Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.